Medication info
Emplgin Met Extended-Release Tablet 25/1000 mg (Empagliflozin, Metformin Hydrochloride)

Emplgin Met Extended-Release Tablet 25/1000 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›25mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Dongkuk Pharmaceutical Co., Ltd.
Appearance
Light yellow, oval-shaped, double-convex extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501720 · Approved 2025.07.09 · Insurance code 653406040

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Patients taking this drug 10/1000 mg extended-release tablets or 25/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this drug 5/1000 mg extended-release tablets or 12.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily. To maintain the extended-release properties, this drug should be swallowed whole and not split, crushed, ground, or chewed. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dose adjustment may be required based on renal function, assessment of renal function is recommended before starting this drug and periodically during treatment. No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this drug may be used with adjustment of the metformin hydrochloride dose as follows: - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to <45 ml/min or estimated glomerular filtration rate (eGFR) decreases to <45 ml/min/1.73m2, this drug should be discontinued immediately. For patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Dongkuk Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Inadequate blood sugar control in adult patients with type 2 diabetes
  • cardiovascular disease
View approved original text

This medication is used to improve blood sugar control in adult patients with type 2 diabetes who are taking empagliflozin and metformin together. It acts as an adjunct to diet and exercise for patients who are not adequately controlled on diet and exercise alone. It can be administered to patients with type 2 diabetes who also have cardiovascular disease; however, in such cases, careful use should be guided by the clinical study information from a specialist. This medication effectively helps control blood sugar, thereby improving patient health.

How to take

Adult dose

The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Patients taking this drug 10/1000 mg extended-release tablets or 25/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this drug 5/1000 mg extended-release tablets or 12.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily. To maintain the extended-release properties, this drug should be swallowed whole and not split, crushed, ground, or chewed. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dose adjustment may be required based on renal function, assessment of renal function is recommended before starting this drug and periodically during treatment. No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this drug may be used with adjustment of the metformin hydrochloride dose as follows: - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to <45 ml/min or estimated glomerular filtration rate (eGFR) decreases to <45 ml/min/1.73m2, this drug should be discontinued immediately. For patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Precautions

This medication is used for the treatment of diabetes and contains two components that assist in blood sugar control. Care should be taken while taking this medication as there is a risk of a rare side effect called severe lactic acidosis. Lactic acidosis occurs when there is an excessive build-up of lactic acid in the body, which can lead to severe conditions and can sometimes be life-threatening. When used with other diabetes medications, hypoglycemia may occur, so blood sugar levels should be monitored frequently, and medication dosage should be adjusted as necessary in consultation with a physician. This medication should not be administered to patients with severely impaired kidney function, acute renal issues, severe infections, heart failure, or certain specific health conditions. Before and after tests involving iodine contrast agents, this medication should be temporarily discontinued due to the risk of deteriorated kidney function and lactic acidosis, and should only be resumed once kidney function has returned to normal. It is safer for pregnant or breastfeeding women to avoid using this medication; if breastfeeding, nursing should be halted. This medication may lead to fluid volume loss, so caution is advised if there are symptoms of dehydration or risk of fluid loss. Additionally, this medication may increase the risk of genital infections and urinary tract infections, so any signs of infection should prompt immediate consultation with a physician. As it may decrease vitamin B12 levels, blood tests to monitor vitamin B12 levels are recommended for individuals on this medication for long periods. Elderly patients or those with poor kidney function should have their kidney function thoroughly evaluated before starting this medication and should regularly monitor their kidney function. Alcohol consumption should be avoided while taking this medication, as alcohol can increase the risk of lactic acidosis. If symptoms such as vomiting, diarrhea, severe muscle pain, or breathing difficulties occur, immediate medical assistance should be sought, as these symptoms may indicate lactic acidosis or ketoacidosis. The tablet should be swallowed whole and not chewed, crushed, or divided, and it is normal for the tablet shell to pass in stool. This medication may interact with other drugs, so it is essential to inform your physician or pharmacist about any other medications you are taking. In cases of overdose, there is a risk of hypoglycemia or lactic acidosis, so medication dosage should not be changed without a doctor's direction, and immediate hospital visit is required in case of an overdose.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased and deficiency of vitamin B12
  • ketoacidosis
  • lactic acidosis
  • nausea
  • vomiting
  • diarrhea
Show 209 more
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • taste disturbance
  • itching
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • decreased fluid volume
  • weight loss
  • headache
  • dizziness
  • insomnia
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • urinary calculi
  • cervical inflammation
  • hyperglycemia
  • hyponatremia
  • vulvar pruritus
  • genital pruritus
  • anxiety
  • angina
  • myocardial infarction
  • deep vein thrombosis
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • back pain
  • glaucoma
  • pathological myopia
  • retinal detachment
  • retinal vein occlusion
  • tears of the retina
  • epistaxis
  • asthma
  • exertional dyspnea
  • productive cough
  • allergic rhinitis
  • cough
  • positional vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodules
  • dermal cysts
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrosis
  • eye discomfort
  • eye congestion
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • nasopharyngitis
  • shingles
  • positional dizziness
  • sensory loss
  • perceptual disturbances
  • amnesia
  • carotid stenosis
  • diabetic neuropathy
  • facial paralysis
  • intracranial aneurysm
  • memory impairment
  • neuralgia
  • Parkinsonism
  • polyneuropathy
  • sensory disorders
  • drowsiness
  • CNS-origin vertigo
  • fatigue
  • peripheral edema
  • facial edema
  • peripheral swelling
  • facial swelling
  • chills
  • strange sensations
  • swelling
  • pain
  • puncture site pain
  • chest pain
  • weakness
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weight gain
  • ECG abnormalities
  • decreased hemoglobin
  • increased hemoglobin
  • Helicobacter test positive
  • positive urine red blood cells
  • ureterolithiasis
  • acute kidney injury
  • chronic kidney disease
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urine
  • benign prostatic hyperplasia
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • vaginal discharge
  • hypoglycemia
  • decreased appetite
  • obesity
  • acanthosis nigricans
  • hyperlipidemia
  • dermal cysts
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrosis
  • eye discomfort
  • eye congestion
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • productive cough
  • allergic rhinitis
  • cough
  • positional vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodules
  • constipation
  • diarrhea
  • dyspepsia
  • abdominal pain
  • nausea
  • gastritis
  • gastrointestinal disorders
  • nasopharyngitis
  • shingles
  • dizziness
  • headache
  • chest discomfort
  • chest pain
  • weakness
  • vulvar pruritus
  • genital pruritus
  • unstable angina
  • hypertension
  • anxiety
  • insomnia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. The appropriate storage temperature is room temperature between 1 to 30 degrees Celsius. Avoid storing it in excessively hot or cold areas.

Appearance and packaging

Appearance

Light yellow, oval-shaped, double-convex extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.